Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 8Active not recruiting 3Completed 2Withdrawn 1Unknown 1Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 425Neoplasms 284Carcinoma, Non-Small-Cell Lung 274Colorectal Neoplasms 236Prostatic Neoplasms 173Lung Neoplasms 171Carcinoma, Hepatocellular 157Stomach Neoplasms 126Leukemia, Myeloid, Acute 120Pancreatic Neoplasms 118Multiple Myeloma 106Recurrence 100Uterine Cervical Neoplasms 97Squamous Cell Carcinoma of Head and Neck 89Neoplasm Metastasis 88Rectal Neoplasms 87Ovarian Neoplasms 81Triple Negative Breast Neoplasms 78Small Cell Lung Carcinoma 72Head and Neck Neoplasms 70Brain Neoplasms 70Glioblastoma 65Esophageal Neoplasms 65Endometrial Neoplasms 59Colonic Neoplasms 59Melanoma 56Hematologic Neoplasms 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Motor Activity 48Glioma 48

Interventions

poly ICLC 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Fibrolamellar hepatocellular carcinoma × Clear all
NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Not yet recruiting
27 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡